2011
DOI: 10.1136/jmedgenet-2011-100653
|View full text |Cite
|
Sign up to set email alerts
|

Mutations inPRRT2result in paroxysmal dyskinesias with marked variability in clinical expression

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

10
98
1
1

Year Published

2012
2012
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 90 publications
(110 citation statements)
references
References 19 publications
10
98
1
1
Order By: Relevance
“…The c.649dupC mutation identified in the family with BFIS and hemiplegic migraine was also identified in 5 other families in our series (figure 2) and in several already published families. [10][11][12][13][14] However, hemiplegic migraine was present only in this family (figure 2, family 11), possibly suggesting an interfamilial phenotypic variability and the interaction of PRRT2 with genetic modifiers.…”
mentioning
confidence: 79%
See 2 more Smart Citations
“…The c.649dupC mutation identified in the family with BFIS and hemiplegic migraine was also identified in 5 other families in our series (figure 2) and in several already published families. [10][11][12][13][14] However, hemiplegic migraine was present only in this family (figure 2, family 11), possibly suggesting an interfamilial phenotypic variability and the interaction of PRRT2 with genetic modifiers.…”
mentioning
confidence: 79%
“…The p.Arg217-Profs*8 is a recurrent frameshift, loss of function mutation 13 that has also been identified in families and in sporadic patients with paroxysmal kinesigenic dyskinesias with or without infantile convulsions and benign familial infantile epilepsy. [9][10][11][12][13][14] The analysis of additional BFIS families led us to identify the c.649dupC in 3 additional familial cases and in the 2 sporadic cases (table, figure 2). In one of the 2 sporadic patients, the mutation occurred de novo.…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Sanger sequencing of PRRT2 revealed the recognized pathogenic (c.649_650InsC p.P217fsX7) heterozygous mutation [2][3][4][5][6][7] in all eight clinically affected individuals as well as in three of the seven clinically unaffected individuals (Fig. 1).…”
mentioning
confidence: 99%
“…Attacks usually respond to low-dose carbamazepine [1]. Mutations in PRRT2 have been identified as a cause of autosomal dominant PKD [2] and replicated in other studies [3][4][5][6][7]. It remains important to report the clinical characteristics of genetically defined families in order to fully describe the clinical syndrome, including the presence of additional associated features beyond the movement disorder.…”
mentioning
confidence: 99%